Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Enzyme stories

Nov 19, 2026

Sanofi wins first FDA approval for neurological symptoms of Gaucher disease

The FDA approved Sanofi's Infilbray, a brain-penetrating small molecule that is the first therapy cleared in the US to treat the neurological symptoms of Gaucher disease type 3.

Nov 19, 2026·3 sources
00

Top claims

  • ▪The Infilbray label notes that the drug may increase the risk of suicidal thoughts and behavior
  • ▪Venglustat did not meet the goals of a Phase 3 test in Fabry disease, another rare enzyme deficiency, results reported prior to November 19, 2026
  • ▪The most common adverse effects reported in the Infilbray Phase 3 trial included diarrhea, an enlarged spleen, and nausea

Topics

Rare diseasesPharmaceutical IndustryNeurodegenerationFDA drug approvalDrug Policy, Pricing & ApprovalClinical trialsGenetic diseases

Related entities

EuropeJapanPfizer